Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 5Terminated 3Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Other hematologic neoplasm 2Myeloid 2Lymphoid 2

Conditions

Leukemia, Myeloid, Acute 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Hematologic Neoplasms 5Myelodysplastic Syndromes 4Tuberous Sclerosis 2Recurrence 2Primary Myelofibrosis 2Myeloproliferative Disorders 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Lymphocytic, Chronic, B-Cell 2Epilepsy 2Bronchiolitis Obliterans Syndrome 2Thyroid Neoplasms 1Solid Tumor 1Sarcoma 1Prostate Cancer Recurrent 1Non-Malignant Neoplasm 1Melanoma 1Lymphoma, T-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Lymphoma 1Lymphangioleiomyomatosis 1Leukemia, Prolymphocytic 1Leukemia, Plasma Cell 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid 1

Interventions

ruxolitinib 6Specimen Handling 6Stem Cell Transplantation 5Cyclophosphamide 4fludarabine 3Mycophenolic Acid 3Biopsy 311-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 3Whole-Body Irradiation 2Tacrolimus 2Sirolimus 2Methotrexate 2Melphalan 2Hematopoietic Stem Cell Transplantation 2Blood Component Removal 2thymoglobulin 1talazoparib 1tagraxofusp 1reparixin 1poly ICLC 1piperine 1pegylated granulocyte colony-stimulating factor 1merphos 1letermovir 1fludarabine phosphate 1fedratinib 1demethoxycurcumin 1daratumumab 1bomedemstat 1axatilimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Primary Myelofibrosis × Sirolimus × Clear all
NCT04888741 2026-05-05

MoTD

University of Birmingham

Phase 2 Recruiting
400 enrolled
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

NCT05805605 2025-07-01

Allo HSCT Using RIC and PTCy for Hematological Diseases

Masonic Cancer Center, University of Minnesota

Phase 2 Recruiting
56 enrolled
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Burkitt Lymphoma, Leukemia, Myeloid, Leukemia, Plasma Cell, Lymphoma, Follicular, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Biphenotypic, Acute, Leukemia, Prolymphocytic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, T-Cell, Lymphoma, B-Cell, Marginal Zone, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡